NCT05923736 Cardiovascular Risk in Digital Osteoarthritis
| NCT ID | NCT05923736 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Clermont-Ferrand |
| Condition | Osteoarthritis Hand |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2023-10-04 |
| Primary Completion | 2025-10-04 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 100 participants in total. It began in 2023-10-04 with a primary completion date of 2025-10-04.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this cross-sectional case control study is to investigate the cardiovascular risk in digital osteoarthritis. This study aims to compare the cardiovascular risk between group of patients with digital osteoarthritis and control group of patients with non-osteoarthritis disease paired by measurement of carotid intima-media thickness. All participants will undergo an ultrasound scan to measure carotid intima media thickness, a clinical assessment with the rheumatologist and a cardiovascular risk assessment.
Eligibility Criteria
Inclusion Criteria: For all subjects: * Adult male or female subject * Able to give informed consent to participate in research * Affiliated with a Social Security plan For the digital osteoarthritis group: * Consultant in Rheumatology at Clermont-Ferrand University Hospital * Affected by digital osteoarthritis meeting ACR diagnostic criteria with radiographic signs of osteoarthritis validated by a radiologist. For the control group : * Rheumatology consultant at the Clermont-Ferrand University Hospital or hospitalized in this department for a non-arthritic, non-rheumatic pathology. * Patients with spinal disc pathology (lumbago, radiculalgia due to disco-radicular conflict) or non-severe osteoporosis, i.e. with a densitometric T score between -2.5 and -3 DS. Exclusion Criteria: For all topics : * Refusal to participate * Pregnant women, nursing mothers * Subjects under guardianship or curatorship, deprived of liberty, or under court protection For the digital osteoarthritis group: \- Existence of diagnostic arguments for another inflammatory rheumatism (rheumatoid arthritis, spondylarthritis, psoriatic arthritis, lupus, gout, chondrocalcinosis...) or another arthrosic localization (gonarthrosis, coxarthrosis, discarthrosis) symptomatic at the time of inclusion or affecting daily activities. For the control group : * Existence of chronic inflammatory rheumatism (rheumatoid arthritis, spondylitis, psoriatic arthritis, lupus, gout, chondrocalcinosis...) * Existence of digital osteoarthritis * Existence of another painful arthritic site (knee, hip, rachi) Existence of finger pain, whatever the etiology.
Contact & Investigator
Sylvain Mathieu
PRINCIPAL INVESTIGATOR
University Hospital, Clermont-Ferrand
Frequently Asked Questions
Who can join the NCT05923736 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Osteoarthritis Hand. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05923736 currently recruiting?
Yes, NCT05923736 is actively recruiting participants. Contact the research team at promo_interne_drci@chu-clermontferrand.fr for enrollment information.
Where is the NCT05923736 trial being conducted?
This trial is being conducted at Clermont-Ferrand, France.
Who is sponsoring the NCT05923736 clinical trial?
NCT05923736 is sponsored by University Hospital, Clermont-Ferrand. The principal investigator is Sylvain Mathieu at University Hospital, Clermont-Ferrand. The trial plans to enroll 100 participants.